Top Markets
#1 Black Phoenix Black Phoenix +166.09%
#2 Islamic Coin Islamic Coin +158.29%
#3 Glidr Glidr +58.56%
#4 DOVU DOVU +20.73%
#5 Cryptopia Cryptopia +20.42%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.03%
#7 MarsCoin MarsCoin +10.05%
#8 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +9.23%
#9 Pons Pons +8.66%
#10 stake.link stake.link +8.27%
Coin of the day
Black Phoenix Black Phoenix
Inställningar
Språk
SVENSKA
Valuta
USD
Tema
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc.

VIAP
Rankning i aktier #41780
VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily... VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily focused on discovering and advancing therapeutic compounds for cardiovascular and metabolic disorders. The firm is building a portfolio of small-molecule drug candidates designed to tackle the root causes of these health issues, such as vascular inflammation, elevated cholesterol and triglyceride levels, and insulin resistance or diabetes. Notable candidates in their development pipeline include: VIA-3196: A liver-specific thyroid hormone receptor (THR) beta agonist, poised for Phase 1 clinical studies. This drug aims to mitigate dyslipidemia, addressing high LDL cholesterol, elevated triglycerides, and Lp(a) levels. A Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor: Currently in preclinical development for treating type 2 diabetes, with promising potential for weight management and other lipid disorders. VIA-2291: A 5-Lipoxygenase inhibitor that has successfully completed its third Phase 2 clinical trial. Its purpose is to target atherosclerotic plaque, a significant contributor to heart attacks, strokes, and various other vascular diseases. VIA Pharmaceuticals has also forged two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. These collaborations pertain to their THR beta agonist program and several compounds from their preclinical DGAT1 metabolic disorders initiative. Established in 2004, the company's headquarters are located in San Francisco, California.
Aktiekurs
$0.0005
Senast synkroniserad: 2026-08-11
Marknadsvärde
$10.28K
Förändring (1 dag)
0.00%
Förändring (1 år)
0.00%
Land
US
Handel VIA Pharmaceuticals, Inc. (VIAP)

Kategori

Healthcare
Aktiekurshistorik för VIA Pharmaceuticals, Inc. (VIAP)
Högsta slutkurs: $0.00 den 2026-08-01

Lägsta slutkurs: $5.07 den 2007-06-01
Aktiekurshistorik för VIA Pharmaceuticals, Inc. från 2007 till 2026
Årlig aktiekursutveckling
År Prestanda
2026 (TTM) 0.00%
2025 10.50%
2024 45,147.62%
2023 0.00%
2022 0.00%
2021 -99.97%
2020 10.50%
2019 6.53%
2018 -48.67%
2017 89.41%
2016 -30.00%
2015 -73.45%
2014 11.70%
2013 -20.93%
2012 118.55%
2011 -85.81%
2010 -81.24%
2009 64.56%
2008 -92.98%
2007 0.00%
Aktiekurs för liknande företag eller konkurrenter
Företag Aktiekurs Förändring 1år% Land
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $59.08 62.03%
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 $49.68 72.21%
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 $184.45 43.36%
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 $62.39 4.91%
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 $113.04 55.27%
US